Since the discovery of the double-helical structure of DNA and postulation of the central dogma of molecular biology, stating that the flow of genetic information goes from DNA to RNA to protein, the ...

While mRNA vaccines have received intense attention of late, another class of nucleic acid therapeutics has been growing steadily in recent years. Its impact could be equally profound. Nucleic acid ...

Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA products (mRNA), most notably used for vaccine production against the recent SARS-CoV-2 pandemic. In this ...

Researchers from IOCB Prague have discovered a new type of substances capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells, from basic building blocks ...

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics. More specifically, this study includes ideas on the design of lipid nanoparticle (LNP) ...

The two most successful coronavirus vaccines developed in the U.S. – the Pfizer and Moderna vaccines – are both mRNA vaccines. The idea of using genetic material to produce an immune response has ...

Nucleic acid technology came of age during COVID-19 with biopharma firms developing, testing, mass producing, and shipping mRNA vaccines in record time. However, as the pandemic ebbs, the industry now ...

Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic ...

Deborah Fuller is co-founder of Orlance, Inc, a biotechnology company developing a needle free technology to deliver RNA and DNA vaccines. She also serves as a scientific advisor for HDT Bio, a ...

SAN DIEGO, February 03, 2025--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an ...

SINGAPORE - A cutting-edge mRNA production laboratory that can quickly produce materials for pre-clinical or animal studies for vaccines to respond to future pandemics, or drugs to combat cancers and ...